April 20, 2018
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: | Ron Alper |
Re: | Eloxx Pharmaceuticals, Inc. |
Registration Statement on FormS-3 |
FileNo. 333-224207 |
Acceleration Request |
Requested Date: Friday, April 20, 2018
Requested Time: 4:30 P.M. Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on FormS-3(File No. 333-224207) (the “Registration Statement”), to become effective on April 20, 2018, at 4:30 P.M. Eastern Daylight Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Miguel Vega of Cooley LLP, counsel to the Registrant, at (617)937-2319, or in his absence, Barbara Bispham at (212)479-6727.
[Signature page follows]
Very truly yours,
Eloxx Pharmaceuticals, Inc. | ||
By: | /s/ Gregory Weaver | |
Gregory Weaver Chief Financial Officer |
cc: | Robert E. Ward, Eloxx Pharmaceuticals, Inc. |
Miguel Vega, Cooley LLP
Barbara Bispham, Cooley LLP